Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963301 | 0.99 | KDM4E (0.37) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 | |
| SCHEMBL5963135 | 0.96 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 | |
| SCHEMBL5963034 | 0.94 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 | |
| SCHEMBL5963030 | 0.93 | KDM4E (0.36) | KDM4ETAS1R3TAS1R1TYMP | |
| SCHEMBL31293731 | 0.90 | TYMP (0.42) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 | |
| SCHEMBL6929166 | 0.89 | KDM4E (0.37) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 | |
| SCHEMBL6934734 | 0.88 | KDM4E (0.37) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 | |
| SCHEMBL5963153 | 0.85 | TYMP (0.42) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 | |
| SCHEMBL6929037 | 0.85 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 | |
| SCHEMBL7243585 | 0.85 | TYMP (0.42) | KDM4ETAS1R3TAS1R1TYMPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101993-B1 | Oligonucleotides containing 2′-O-modified purines | ISIS PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | ISIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048826-A1 | Oligonucleotides containing 2'-0-modified purines | NSUN2, RNMT, HNRNPL | KDM4E 2006/4885TAS1R3 2968/4885TAS1R1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.